A New Hope for Managing Depression

Depression is a difficult and personal experience and finding the right treatment can often feel overwhelming. At Aurora Direct, we know how important it is to offer options that are both effective and tailored to individual needs. That’s why we’re excited to introduce Flow Neuroscience, a clinically supported treatment that blends technology and therapy to help people experiencing depression.

In this post, we’ll explain what Flow is, how it works and what you can expect along the way. If you or someone you know is exploring new ways to manage depression, this might be just what you need.

What Is Flow?

Flow involves two components:

• A tDCS headset, which stands for transcranial direct current stimulation
• A behavioural therapy app programme

The treatment is designed to address multiple root causes of depression instead of just one. It is only to be used in adults 18+ and under the supervision of an appropriately qualified health practitioner.

What is tDCS?

tDCS is a pain-free and non-invasive brain stimulation method. It delivers gentle currents to help restore brain activity and reduce depressive symptoms.

The Flow headset targets a part of the brain called the Dorsolateral Prefrontal Cortex, also known as the DLPFC. Research shows that DLPFC tends to be less active in people with depression (Koenigs & Grafman, 2009). Flow uses a weak electrical current using electrodes placed on the forehead to reinforce natural signalling in that brain region. As the stimulation is focused, side effects are generally less common and less severe than many antidepressant medications (Mutz et al, 2019)

How Flow Treatment Works

Flow can be used at home with a standard treatment schedule under the supervision of your qualified health practitioner.

Here’s the typical schedule when used:

(Flow Neuroscience, 2025)

What Results Can You Expect?

Early phase: It’s normal if the first few sessions don’t feel very different. That doesn’t mean that nothing is happening, it often takes time for the effects to build.

Within weeks: Some users report noticing improvements as early as one session; others may begin to see changes around week four.

By 10 weeks: In clinical trials, 57% of participants achieved remission, meaning their depression symptoms had reduced to a very low level (Woodham et al, 2024).

Could Flow Be Right For You ?

Flow may be suitable if you:

• Are 18 or older with a diagnosis of depression known as major depressive disorder (MDD)
• Want to try a treatment that is non-medication, or to use as an adjunctive treatment.
• Prefer home-based treatment with guidance from your supervising qualified health practitioner.
• Can commit to regular sessions (usually 5 per week in the early phase) (Flow Neuroscience, 2025)

If you’d like to find out whether Flow might be right for you or explore how it can fit alongside your current treatment, please read the information provided on our website or speak to your health practitioner. If you We’re here to help you understand your options and support your journey.

ARTG No. 509725 and 510555
Aurora BioScience Pty Ltd is the Australian TGA sponsor for Flow Neuroscience. Flow – Transcranial Direct Current stimulator (tDCS) is only to be used under the supervision of an appropriately qualified health practitioner.

References
Koenigs, M., & Grafman, J. (2009). The functional neuroanatomy of depression: Distinct roles for ventromedial and dorsolateral prefrontal cortex. Behavioural Brain Research, 201(2), 239–243. https://doi.org/10.1016/j.bbr.2009.03.004

Flow Neuroscience. (2025). Clinical outcomes and real-world data. Retrieved October 2025, from https://hcp.flowneuroscience.com/outcomes_clinical-data/

Woodham, R. D., Selvaraj, S., Lajmi, N., et al. (2024). Transcranial direct current stimulation for depression: A multicentre randomised controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03007-x

Mutz, J., Edgcumbe, D. R., Brunoni, A. R., & Fu, C. H. Y. (2019). Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis of randomised sham-controlled trials. Molecular Psychiatry, 24, 1644–1656. https://doi.org/10.1038/s41380-018-0108-9